1 |
World Health Organization. WHO Expert Committee on Specifications for Pharmaceutical Preparations: Forty-eighth Report[M]. World Health Organization, 2014:401.
|
2 |
蒋朱明,詹思延,贾晓巍,等. 制订/修订《临床诊疗指南》的基本方法及程序[J]. 中华医学杂志,2016, 96(4):250-253.
|
3 |
Brouwers MC, Kho ME, Browman GP, et al. AGREE II: Advancing guideline development, reporting and evaluation in health care[J]. CMAJ, 2010, 182(18):E839-E842.
|
4 |
Chen YL, Yang K, Marušić A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement[J]. Ann Intern Med, 2017, 166(2):128-132.
|
5 |
Centre for Evidence-Based Medicine (CEBM), University of Oxford. Oxford Centre for Evidence-Based Medicine: Levels of Evidence (March 2009)[DB/OL]. [2023-02-01].
URL
|
6 |
Liu HL, He X, Wang YD, et al. Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation[J]. Hepatol Int, 2020, 14(4):432-436.
|
7 |
Fraser J, Mousley J, Testro A, et al. Clinical presentation, treatment, and mortality rate in liver transplant recipients with coronavirus disease 2019: A systematic review and quantitative analysis[J]. Transplant Proc, 2020, 52(9):2676-2683.
|
8 |
Wong GLH, Wong VWS, Thompson A, et al. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement[J]. Lancet Gastroenterol Hepatol, 2020, 5(8):776-787.
|
9 |
Ma E, Ai JW, Zhang Y, et al. Omicron infections profile and vaccination status among 1881 liver transplant recipients: A multi-centre retrospective cohort[J]. Emerg Microbes Infect, 2022, 11(1):2636-2344.
|
10 |
Raja MA, Mendoza MA, Villavicencio A, et al. COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature[J]. Transplant Rev (Orlando), 2021, 35(1):100588.
|
11 |
Jayant K, Reccia I, Virdis F, et al. COVID-19 in hospitalized liver transplant recipients: an early systematic review and meta-analysis[J]. Clin Transplant, 2021, 35(4):e14246.
|
12 |
Duarsa GWK, Sugianto R, Yusari IGAAA, et al. Predictor factor for worse outcomes in kidney transplant recipients infected with coronavirus disease 2019: a systematic review and meta-analysis[J]. Transpl Immunol, 2023, 76:101739.
|
13 |
Kulkarni AV, Tevethia HV, Premkumar M, et al. Impact of COVID-19 on liver transplant recipients-a systematic review and meta-analysis[J]. EClinicalMedicine, 2021, 38:101025.
|
14 |
Bansal A, Kumar A, Bansal RM, et al. The impact of comorbidities on clinical course and outcome, in kidney transplant recipients with COVID-19: a systematic review and analysis[J]. Indian J Transpl, 2020, 14(4):275.
|
15 |
Bartelt L, van Duin D. An overview of COVID-19 in solid organ transplantation[J]. Clin Microbiol Infect, 2022, 28(6):779-784.
|
16 |
Kremer D, Pieters TT, Verhaar MC, et al. A systematic review and meta-analysis of COVID-19 in kidney transplant recipients: lessons to be learned[J]. Am J Transplant, 2021, 21(12):3936-3945.
|
17 |
Mahalingasivam V, Craik A, Tomlinson LA, et al. A systematic review of COVID-19 and kidney transplantation[J]. Kidney Int Rep, 2021, 6(1):24-45.
|
18 |
An W, Wang Q, Kim TE, et al. Clinical characteristics and outcome of coronavirus disease 2019 infection in patients with solid organ transplants: a systematic review and meta-analysis[J]. J Infect Public Health, 2022, 15(3):365-372.
|
19 |
Ho QY, Sultana R, Lee TL, et al. Coronavirus disease 2019 in kidney transplant recipients: a systematic review and meta-analysis[J]. Singapore Med J, 2021.
|
20 |
Moosavi SA, Mashhadiagha A, Motazedian N, et al. COVID-19 clinical manifestations and treatment strategies among solid-organ recipients: a systematic review of cases[J]. Transpl Infect Dis, 2020, 22(6):e13427.
|
21 |
Diaz-Arocutipa C, Carvallo-Castañeda D, Luis-Ybañez O, et al. COVID-19 in heart transplant recipients during February-August 2020: a systematic review[J]. Clin Transplant, 2021, 35(9):e14390.
|
22 |
Morris S, Anjan S, Pallikkuth S, et al. Reinfection with SARS-CoV-2 in solid-organ transplant recipients: incidence density and convalescent immunity prior to reinfection[J]. Transpl Infect Dis, 2022, 24(3):e13827.
|
23 |
Vitale J, Mumoli N, Clerici P, et al. Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in Lombardy, Italy[J]. JAMA Intern Med, 2021, 181(10):1407-1408.
|
24 |
Medić S, Anastassopoulou C, Lozanov-Crvenković Z, et al. Risk and severity of SARS-CoV-2 reinfections during 2020-2022 in Vojvodina, Serbia: a population-level observational study[J]. Lancet Reg Health Eur, 2022, 20:100453.
|
25 |
Qureshi AI, Baskett WI, Huang W, et al. Reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients undergoing serial laboratory testing[J]. Clin Infect Dis, 2022, 74(2):294-300.
|
26 |
中华人民共和国国家卫生健康委员会. 新型冠状病毒感染诊疗方案(试行第十版) [EB/OL].(2023-01-06)[2023-02-01].
URL
|
27 |
World Health Organization. Public health surveillance for COVID-19: interim guidance, 22 July 2022[DB/OL]. (2022-07-22) [2023-01-30].
URL
|
28 |
中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第九版)[EB/OL].(2022-03-14)[2023-02-01].
URL
|
29 |
Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens[J]. JAMA, 2020, 323(18):1843-1844.
|
30 |
Marjot T, Webb GJ, Barritt AS, et al. COVID-19 and liver disease: mechanistic and clinical perspectives[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(5):348-364.
|
31 |
Chen ZF, Xu WJ, Ma WS, et al. Clinical laboratory evaluation of COVID-19[J]. Clin Chim Acta, 2021, 519:172-182.
|
32 |
Karakoyun I, Colak A, Turken M, et al. Diagnostic utility of C-reactive protein to albumin ratio as an early warning sign in hospitalized severe COVID-19 patients[J]. Int Immunopharmacol, 2021, 91:107285.
|
33 |
Liu XK, Yue XP, Liu FR, et al. Analysis of clinical features and early warning signs in patients with severe COVID-19: a retrospective cohort study[J/OL]. PLoS One, 2020, 15(6):e0235459.
|
34 |
Wang XR, Che QL, Ji XX, et al. Correlation between lung infection severity and clinical laboratory indicators in patients with COVID-19: a cross-sectional study based on machine learning[J]. BMC Infect Dis, 2021, 21(1):192.
|
35 |
Guo J, Wang S, Xia H, et al. Cytokine signature associated with disease severity in COVID-19[J]. Front Immunol, 2021, 12:681516.
|
36 |
Mitchell O, Cosar AM, Malik MU, et al. Late liver function test abnormalities post-adult liver transplantation: a review of the etiology, investigation, and management[J]. Hepatol Int, 2016, 10(1):106-114.
|
37 |
Wadei HM, Lee DD, Croome KP, et al. Early allograft dysfunction after liver transplantation is associated with short- and long-term kidney function impairment[J]. Am J Transplant, 2016, 16(3):850-859.
|
38 |
Buchan TA, Moayedi Y, Truby LK, et al. Incidence and impact of primary graft dysfunction in adult heart transplant recipients: a systematic review and meta-analysis[J]. J Heart Lung Transplant, 2021, 40(7):642-651.
|
39 |
Shah RJ, Diamond JM. Primary graft dysfunction (PGD) following lung transplantation[J]. Semin Respir Crit Care Med, 2018, 39(2):148-154.
|
40 |
Bhat KA, Madi D, Bhat S, et al. Profile of secondary bacterial and fungal infections in hospitalized COVID-19 patients in a tertiary care centre[J]. Infect Drug Resist, 2022, 15:5705-5714.
|
41 |
Patel P, DeCuir J, Abrams J, et al. Clinical characteristics of multisystem inflammatory syndrome in adults: a systematic review[J]. JAMA Netw Open, 2021, 4(9):e2126456.
|
42 |
Weiss-Tessbach M, Ratzinger F, Obermueller M, et al. Biomarkers for differentiation of coronavirus disease 2019 or extracorporeal membrane oxygenation related inflammation and bacterial/fungal infections in critically ill patients: a prospective observational study[J]. Front Med (Lausanne), 2022, 9:917606.
|
43 |
Nimmo A, Gardiner D, Ushiro-Lumb I, et al. The global impact of COVID-19 on solid organ transplantation: two years into a pandemic[J]. Transplantation, 2022, 106(7):1312-1329.
|
44 |
APASL Covid-19 Task Force, Lau G, Sharma M. Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations[J]. Hepatol Int, 2020, 14(4):415-428.
|
45 |
Gandolfini I, Crespo M, Hellemans R, et al. Issues regarding COVID-19 in kidney transplantation in the ERA of the Omicron variant: a commentary by the ERA Descartes Working Group[J]. Nephrol Dial Transplant, 2022, 37(10):1824-1829.
|
46 |
Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for high-risk, nonhospitalized adults with Covid-19[J]. N Engl J Med, 2022, 386(15):1397-1408.
|
47 |
阿兹夫定片说明书[EB/OL]. [2023-02-01].
URL
|
48 |
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients[J]. N Engl J Med, 2022, 386(6):509-520.
|
49 |
Cao Z, Gao W, Bao H, et al. VV116 versus Nirmatrelvir-Ritonavir for oral treatment of Covid-19[J]. N Engl J Med, 2023, 388(5):406-417.
|
50 |
Helleberg M, Niemann CU, Moestrup KS, et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of Remdesivir therapy[J]. J Infect Dis, 2020, 222(7):1103-1107.
|
51 |
Trottier CA, Wong B, Kohli R, et al. Dual antiviral therapy for persistent COVID-19 and associated organizing pneumonia in an immunocompromised host[J]. Clin Infect Dis, 2022:ciac847.
|
52 |
Martinez MA, Chen TY, Choi H, et al. Extended Remdesivir infusion for persistent coronavirus disease 2019 infection[J]. Open Forum Infect Dis, 2022, 9(8):ofac382.
|
53 |
Dosing & Side Effects. Olumiant® (baricitinib)[EB/OL]. [2023-02-01].
URL
|
54 |
Tocilizumab (Actemra) [EB/OL]. [2023-02-01].
URL
|
55 |
Yin S, Wang X, Song T. Tacrolimus use and COVID-19 infection in patients after solid organ transplantation[J]. Gastroenterology, 2021, 161(2):728-730.e1.
|
56 |
Kolonko A, Kuczaj AA, Musialik J, et al. Clinical insights into the role of immunosuppression in solid organ transplant recipients with COVID-19[J]. Pol Arch Intern Med, 2022, 132(2):16139.
|
57 |
Belli LS, Fondevila C, Cortesi PA, et al. Protective role of Tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR Multi-center European Study[J]. Gastroenterology, 2021, 160(4):1151-1163.e3.
|
58 |
Karruli A, Spiezia S, Boccia F, et al. Effect of immunosuppression maintenance in solid organ transplant recipients with COVID-19: systematic review and meta-analysis[J]. Transpl Infect Dis, 2021, 23(4):e13595.
|
59 |
Colmenero J, Rodríguez-Perálvarez M, Salcedo M, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients[J]. J Hepatol, 2021, 74(1):148-155.
|
60 |
Yadav DK, Adhikari VP, Ling Q, et al. Immunosuppressants in liver transplant recipients with coronavirus disease 2019: capability or catastrophe?-a systematic review and meta-analysis[J]. Front Med (Lausanne), 2021, 8:756922.
|
61 |
Lemaitre F, Budde K, Van Gelder T, et al. Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir/ritonavir in patients with COVID-19[J]. Ther Drug Monit, 2022.
|
62 |
Lemaitre F, Grégoire M, Monchaud C, et al. Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: guidelines from the French Society of Pharmacology and Therapeutics (SFPT) [J]. Therapie, 2022, 77(5):509-521.
|
63 |
Lange NW, Salerno DM, Jennings DL, et al. Nirmatrelvir/ritonavir use: managing clinically significant drug-drug interactions with transplant immunosuppressants[J]. Am J Transplant, 2022, 22(7):1925-1926.
|
64 |
Salerno DM, Jennings DL, Lange NW, et al. Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients[J]. Am J Transplant, 2022, 22(8):2083-2088.
|
65 |
Devresse A, Sébastien Briol, De Greef J, et al. Safety, efficacy, and relapse of Nirmatrelvir-Ritonavir in kidney transplant recipients infected with SARS-CoV-2[J]. Kidney Int Rep, 2022, 7(11):2356-2363.
|
66 |
Liu Y, Liu B, Zhang Y, et al. Intestinal absorption mechanisms of 2′-deoxy-2′-β-fluoro-4′-azidocytidine, a cytidine analog for AIDS treatment, and its interaction with P-glycoprotein, multidrug resistance-associated protein 2 and breast cancer resistance protein[J]. Eur J Pharm Sci, 2017, 105:150-158.
|
67 |
Liu Y, Wang Y, Peng Y, et al. Effects of the antiretroviral drug 2′-deoxy-2′-β-fluoro-4′-azidocytidine (FNC) on P-gp, MRP2 and BCRP expressions and functions[J]. Pharmazie, 2018, 73(9):503-507.
|
68 |
Hirai T, Mizuta A, Sasaki T, et al. Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient[J]. Int J Clin Pharmacol Ther, 2022, 60(10):439-444.
|
69 |
Nakamura J, Yanagida M, Saito K, et al. Epstein-barr virus encephalitis in a patient with rheumatoid arthritis[J]. Mod Rheumatol Case Rep, 2022, 6(2):160-162.
|
70 |
Sugawara E, Matsui K, Amasaki Y. Cytomegalovirus enteritis in a patient with rheumatoid arthritis receiving Baricitinib[J]. J Rheumatol, 2020, 47(12):1835-1836.
|
71 |
Bilaloglu S, Aphinyanaphongs Y, Jones S, et al. Thrombosis in hospitalized patients with COVID-19 in a New York City Health System[J]. JAMA, 2020, 324(8):799-801.
|
72 |
Menter T, Haslbauer JD, Nienhold R, et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction[J]. Histopathology, 2020, 77(2):198-209.
|
73 |
Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19[J]. J Thromb Haemost, 2020, 18(8):1995-2002.
|
74 |
Nicolai L, Leunig A, Brambs S, et al. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy[J]. Circulation, 2020, 142(12):1176-1189.
|
75 |
Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study[J]. Ann Intern Med, 2020, 173(4):268-277.
|
76 |
Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19[J]. N Engl J Med, 2020, 383(25):2451-2460.
|
77 |
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study[J]. Lancet, 2020, 395(10229):1054-1062.
|
78 |
Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia[J]. J Thromb Haemost, 2020, 18(6):1421-1424.
|
79 |
Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19[J]. Thromb Res, 2020, 191:145-147.
|
80 |
Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy[J]. Thromb Res, 2020, 191:9-14.
|
81 |
Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19[J]. J Am Coll Cardiol, 2020, 76(16):1815-1826.
|
82 |
Task Force for the management of COVID-19 of the European Society of Cardiology. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up[J]. Eur Heart J, 2022, 43(11):1059-1103.
|
83 |
Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19[J]. J Thromb Haemost, 2020, 18(5):1023-1026.
|
84 |
Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2020, 75(23):2950-2973.
|
85 |
Hoy SM. Amubarvimab/Romlusevimab: first approval[J]. Drugs, 2022, 82(12):1327-1331.
|
86 |
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial[J]. Lancet Infect Dis, 2022, 22(5):622-635.
|
87 |
中华医学会呼吸病学分会,中国医师协会呼吸医师分会危重症医学专家组. 奥密克戎变异株所致重症新型冠状病毒感染临床救治专家推荐意见[J]. 中华结核和呼吸杂志,2023, 46(2):101-110.
|
88 |
Siemieniuk RAC, Chu DK, Kim LHY, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline[J]. BMJ, 2018, 363:k4169.
|
89 |
Nevermann N, Wiering L, Wu H, et al. Transplantation programs facing lack of empirical evidence on SARS-CoV-2 vaccination: a society recommendation consensus update[J]. Transpl Infect Dis, 2021, 23(4):e13696.
|
90 |
National Institutes of Health. Special considerations in solid organ transplant, hematopoietic cell transplant, and cellular immunotherapy candidates, donors, and recipients. COVID-19 Treatment Guidelines[EB/OL]. (2022-12-01) [2023-02-01].
URL
|
91 |
AST, ASTS, ISHLT. Joint statement about COVID-19 vaccination in organ transplant candidates and recipients [EB/OL]. (2022-12-01) [2023-02-01].
URL
|
92 |
WHO. Who needs an additional dose of COVID-19 vaccines?[EB/OL]. (2022-05-17) [2023-02-01].
URL
|
93 |
中华人民共和国国家卫生健康委员会. 新冠病毒疫苗接种技术指南(第一版)[EB/OL].(2021-03-29)[2023-02-01].
URL
|
94 |
Cohen MS, Nirula A, Mulligan MJ, et al. Effect of Bamlanivimab vs Placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial[J]. JAMA, 2021, 326(1):46-55.
|
95 |
Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19[J]. N Engl J Med, 2022, 386(23):2188-200.
|
96 |
Shields AM, Burns SO, Savic S, et al; UK PIN COVID-19 Consortium. COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience[J]. J Allergy Clin Immunol, 2021, 147(3):870-875.e1.
|
97 |
Calabrese C, Kirchner E, Villa-Forte A, et al. Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity[J]. RMD Open, 2022, 8(2):e002557.
|
98 |
Ritschl PV, Nevermann N, Wiering L, et al. Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: a by-proxy society recommendation consensus approach[J]. Am J Transplant, 2020, 20(7):1826-1836.
|
99 |
COVID 19 rapid guideline: renal transplantation[M/OL]. London: National Institute for Health and Care Excellence (NICE). (2020-08-19) [2023-01-30].
URL
|
100 |
Kute VB, Guleria S, Bhalla AK, et al. ISOT consensus statement for the kidney transplant recipient and living donor with a previous diagnosis of COVID-19[J]. Indian J Nephrol, 2022, 32(4):288-290.
|
101 |
Kulkarni AV, Parthasarathy K, Kumar P, et al. Early liver transplantation after COVID-19 infection: the first report[J]. Am J Transplant, 2021, 21(6):2279-2284.
|
102 |
Gut G, Góral A, Dal Canton Z, et al. Kidney transplantation in COVID pandemic-a review of guidelines[J]. J Clin Med, 2021, 10(13):2877.
|
103 |
Mahajan S, Kohli HS, Gupta KL, et al; COVID-19 Working Group of Indian Society of Nephrology. Infection prevention and control guidelines for COVID[J]. Indian J Nephrol, 2020, 30(3):185-187.
|
104 |
Biancone L, Minetti E, De Rosa P, et al. Telemedicine monitoring in the follow-up of kidney transplant recipients: consensus indications from an Italian panel of surgeons and nephrologists after the COVID-19 experience[J]. J Nephrol, 2022, 35(3):725-733.
|
105 |
Sever MS, Vanholder R, Oniscu G, et al. Kidney transplantation during mass disasters - from COVID-19 to other catastrophes: a consensus statement by the DESCARTES Working Group and Ethics Committee of the ERA[J]. Nephrol Dial Transplant, 2022:gfac251.
|